Homologous Recombination Deficiency Clinical Trials

22 clinical trials for Homologous Recombination Deficiency across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Bipolar Androgen Therapy + Carboplatin in mCRPC — RECRUITING · PHASE2
• Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency — RECRUITING · PHASE2
• Olaparib in Patients With HRD Malignant Mesothelioma — RECRUITING · PHASE2
• A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies — RECRUITING · PHASE1
• EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors — RECRUITING · PHASE1
• Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency — NOT_YET_RECRUITING · PHASE2
• Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS) — COMPLETED · PHASE1
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• Functional Analysis of BRCAness — TERMINATED · PHASE2
• The HER Project: HRD in EGFR-mutated NSCLC — ACTIVE_NOT_RECRUITING
• Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer — WITHDRAWN · PHASE2
• Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency — TERMINATED · PHASE2
• Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies — TERMINATED · PHASE1
• Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency — OTHER · PHASE2
• HRD and Resistance to PAPPi in EOC Patients — OTHER
• A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer — COMPLETED
• Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency — TERMINATED · PHASE2
• A Training Set for the HRD Model in EOC — OTHER
• Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer — OTHER · PHASE2
• Homologous Recombination Deficiency Status in Epithelial Ovarian Cancer — OTHER
• Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer — WITHDRAWN · PHASE2

Refine this search